Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. The company's lead product, Ocaliva (obeticholic acid), is an agonist of the farnesoid X receptor (FXR) that is approved for the treatment of primary biliary cholangitis (PBC), a rare and chronic liver disease. Intercept is also developing other FXR agonists for the treatment of nonalcoholic steatohepatitis (NASH), a liver disease that is associated with obesity and metabolic syndrome. The company was founded in 2002 and is headquartered in New York, New York.
Highest paying job titles at Intercept Pharmaceuticals include Territory Sales Representative, Medical Director, and Channel Sales Manager